A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs Trimodulin (Primary)
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms CIGMA
  • Sponsors Biotest AG
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Feb 2015 Planned End Date changed from 1 May 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 02 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top